Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT
…, M Wu, LB Tankó, AA Schubert-Tennigkeit… - Neurology, 2021 - AAN Enterprises
Objective To assess long-term (2 years) effects of bimagrumab in participants with sporadic
inclusion body myositis (sIBM). Methods Participants (aged 36–85 years) who completed the …
inclusion body myositis (sIBM). Methods Participants (aged 36–85 years) who completed the …
[HTML][HTML] Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in …
JA Wedzicha, R Dahl, R Buhl, A Schubert-Tennigkeit… - Respiratory …, 2014 - Elsevier
Background To further assess the safety profile of the fixed-dose combination of indacaterol
and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of …
and glycopyrronium (QVA149) and its monocomponents; we investigated the impact of …
[HTML][HTML] Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial
…, N Fretault, AA Schubert-Tennigkeit… - The Lancet Healthy …, 2021 - thelancet.com
Background Older adult patients (ie, those aged ≥60 years) undergoing surgery for hip
fracture repair frequently experience loss of muscle mass and strength due to poor mobility and …
fracture repair frequently experience loss of muscle mass and strength due to poor mobility and …
[HTML][HTML] Long-term maintenance bronchodilation with indacaterol/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 study
…, Q Wang, AA Schubert-Tennigkeit… - Chronic Obstructive …, 2016 - ncbi.nlm.nih.gov
Background: The objective of the FLIGHT3 study was to evaluate the long-term safety and
efficacy of indacaterol/glycopyrrolate*(IND/GLY) versus an active comparator, IND, in patients …
efficacy of indacaterol/glycopyrrolate*(IND/GLY) versus an active comparator, IND, in patients …
Cardiovascular Safety of QVA149 in Patients With Moderate-to-Severe COPD: Pooled Analysis of FLIGHT1 and FLIGHT2 Clinical Studies
…, T Ayers, D Banerji, S Maitra, AA Schubert-Tennigkeit - Chest, 2015 - journal.chestnet.org
PURPOSE: Monitoring cardiovascular safety is of importance when combining long-acting β
2 agonists (LABA) and long-acting muscarinic antagonists (LAMA)(Tashkin et al. Respir Res…
2 agonists (LABA) and long-acting muscarinic antagonists (LAMA)(Tashkin et al. Respir Res…
QVA149, Twice Daily, Is Well Tolerated in Patients With Moderate-to-Severe COPD and Has a Safety Profile Similar to Placebo: FLIGHT1 and FLIGHT2 Pooled …
…, R Fogel, D Banerji, S Maitra, AA Schubert-Tennigkeit - Chest, 2015 - journal.chestnet.org
PURPOSE: Current guidelines recommend the addition of a second bronchodilator class to
the existing bronchodilator regimen for the effective management of symptoms in moderate-…
the existing bronchodilator regimen for the effective management of symptoms in moderate-…
Long-term safety and tolerability of indacaterol/glycopyrrolate in moderate-to-severe COPD patients from the US: a subgroup analysis from the FLIGHT3 study
GT Ferguson, AA Schubert-Tennigkeit… - D36. COPD: LABA …, 2016 - atsjournals.org
Methods Safety data in the subgroup of US patients from a 52-week, randomized, multi-center,
double-blind, parallel-group and active-controlled FLIGHT3 study was assessed in terms …
double-blind, parallel-group and active-controlled FLIGHT3 study was assessed in terms …
Bimagrumab to Improve Recovery after Hip Fracture in the Elderly: A Randomised, Double-Blind, Placebo-Controlled Phase 2a/b Study
…, N Fretault, AA Schubert-Tennigkeit… - The Lancet Healthy …, 2021 - oak.novartis.com
Background: Elderly patients undergoing surgery for hip fracture repair frequently experience
loss of muscle mass and strength due to immobility, which may delay functional recovery. …
loss of muscle mass and strength due to immobility, which may delay functional recovery. …
D36 ALL TOGETHER NOW: COPD TREATMENT WITH LONG-ACTING BETA AGONISTS AND LONG-ACTING MUSCARINIC ANTAGONISTS: Qva149 Is Safe And …
…, Q Wang, AA Schubert-Tennigkeit… - American Journal of …, 2015 - search.proquest.com
Methods FLIGHT3 was a 52week, multicenter, doubleblind study that randomized patients (1:
1: 1) to QVA149 27.5/12.5 µg bid, QVA149 27.5/25 µg bid and indacaterol 75 µg od, …
1: 1) to QVA149 27.5/12.5 µg bid, QVA149 27.5/25 µg bid and indacaterol 75 µg od, …
Supplementary Appendix for Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium …
JA Wedzicha, R Dahl, R Buhl, A Schubert-Tennigkeit… - resmedjournal.com
INHANCE [1, 2](QAB149B2335S; NCT00463567) R, DB, DD, PB, PG, adaptive, and
seamless pivotal efficacy and safety Stage 1: 801 Stage 2: 1683 Moderate-to-severe COPD …
seamless pivotal efficacy and safety Stage 1: 801 Stage 2: 1683 Moderate-to-severe COPD …